Javara Inc

1. Moderna TX, Inc. $28,989,723 2,094 payments
2. Pfizer Inc. $6,456,512 528 payments
3. Organon LLC $1,713,726 214 payments
4. Sanofi US Services Inc. $1,485,933 147 payments
5. GlaxoSmithKline, LLC. $1,483,536 412 payments
6. Alnylam Pharmaceuticals Inc. $1,274,115 862 payments
7. Sanofi Pasteur Inc. $517,872 77 payments
8. AbbVie, Inc. $428,473 124 payments
9. Genentech, Inc. $338,323 61 payments
10. Mylan Inc. $239,606 61 payments

1. A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health $10,329,245 154 payments
2. A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older $4,650,217 299 payments
3. A Phase 3 Study to Evaluate the Efficacy Immunogenicity and Safety of Respiratory Syncytial Virus RSV Prefusion F Subunit Vaccine in Adults $4,515,585 297 payments
4. A Phase 3, Randomized, Observer-blind, Active-controlled, Case-drivenStudy to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Seasonal Influenza Vaccine Compared with a Licensed Inactivated Seasonal Influenza Vaccine in Adults 50 Years of Age $3,980,852 40 payments
5. A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis $3,635,737 376 payments
6. A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age $3,045,042 224 payments
7. A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Mrna-1403, A Multivalent Candidate Vaccine to Prevent Norovirus Acute Gastroenteritis in Adults 18 Years of Age $1,654,725 38 payments
8. Og-8175A-023 $1,093,559 147 payments
9. A Phase 3 Randomized Observerblinded Study to Evaluate the Efficacy Safety Tolerability and Immunogenicity of A Modified Rna Vaccine Against Influenza Compared to Licensed Inactivated Influenza Vaccine in Healthy Adults 18 Years of Age Or Older $1,033,092 69 payments
10. A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) $708,161 655 payments

1. Patient care $1,713,726 214 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.